JP2003534246A - ＲＡＲα選択的レチノイド化合物と他の抗腫瘍剤との併用による腫瘍の処置 - Google Patents

ＲＡＲα選択的レチノイド化合物と他の抗腫瘍剤との併用による腫瘍の処置

Info

Publication number
JP2003534246A
JP2003534246A JP2001572454A JP2001572454A JP2003534246A JP 2003534246 A JP2003534246 A JP 2003534246A JP 2001572454 A JP2001572454 A JP 2001572454A JP 2001572454 A JP2001572454 A JP 2001572454A JP 2003534246 A JP2003534246 A JP 2003534246A
Authority
JP
Japan
Prior art keywords
compound
mammal
condition
interferon
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2001572454A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003534246A5 (enExample
Inventor
アリサー・ネーム
リチャード・エル・ビアード
ロシャンタ・エイ・チャンドララトナ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of JP2003534246A publication Critical patent/JP2003534246A/ja
Publication of JP2003534246A5 publication Critical patent/JP2003534246A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/66—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings being part of condensed ring systems and singly-bound oxygen atoms, bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
JP2001572454A 2000-04-04 2001-04-02 ＲＡＲα選択的レチノイド化合物と他の抗腫瘍剤との併用による腫瘍の処置 Pending JP2003534246A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US54214800A 2000-04-04 2000-04-04
US09/542,148 2000-04-04
PCT/US2001/010410 WO2001074759A1 (en) 2000-04-04 2001-04-02 Treatment of tumors with rar alpha selective retinoid compounds in combination with other anti-tumor agents

Publications (2)

Publication Number Publication Date
JP2003534246A true JP2003534246A (ja) 2003-11-18
JP2003534246A5 JP2003534246A5 (enExample) 2008-05-15

Family

ID=24162539

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001572454A Pending JP2003534246A (ja) 2000-04-04 2001-04-02 ＲＡＲα選択的レチノイド化合物と他の抗腫瘍剤との併用による腫瘍の処置

Country Status (10)

Country Link
US (1) US6387950B2 (enExample)
EP (2) EP1268405B1 (enExample)
JP (1) JP2003534246A (enExample)
AT (1) ATE331703T1 (enExample)
AU (1) AU2001253045A1 (enExample)
CA (1) CA2405136C (enExample)
DE (1) DE60121145T2 (enExample)
ES (1) ES2267754T3 (enExample)
TW (1) TWI281911B (enExample)
WO (1) WO2001074759A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6903121B1 (en) * 2000-08-17 2005-06-07 Allergan, Inc. Treatment of tumors with acetylenes disubstituted with a phenyl or heteroaromatic group and a substituted chromanyl, thiochromanyl or tetrahydroquinolinyl group in combination with other anti-tumor agents
EP1935869A1 (en) * 2000-10-02 2008-06-25 F. Hoffmann-La Roche Ag Retinoids for the treatment of emphysema
WO2002028810A2 (en) * 2000-10-02 2002-04-11 F. Hoffmann-La Roche Ag Retinoids for the treatment of emphysema
US6620963B1 (en) 2002-09-19 2003-09-16 Allergan, Inc. TRICYCLO[6.2.202,7]DODECA-2(7),3,5-TRIEN-4-CARBONYLAMINO-PHENYL AND TRICYCLO[6.2.202,7]DODECA-2(7),3,5-TRIEN-4-CARBONYLAMINO-HETEROARYL AND RELATED COMPOUNDS HAVING RARα RECEPTOR SELECTIVE BIOLOGICAL ACTIVITY
WO2005093426A2 (en) * 2004-03-26 2005-10-06 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with retinoic acid receptor alpha (rara)
LT1937244T (lt) 2005-09-30 2018-11-12 Io Therapeutics, Llc Vėžio gydymas specifiniais rxr agonistais
EP2685972A4 (en) * 2011-03-14 2014-08-13 Io Therapeutics Inc TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES WITH RAR ALPHA SELECTIVE AGONISTS
US10653650B2 (en) 2011-12-13 2020-05-19 Io Therapeutics, Inc. Treatment of diseases by concurrently eliciting remyelination effects and immunomodulatory effects using selective RXR agonists
CN110151745A (zh) 2011-12-13 2019-08-23 Io治疗公司 使用rxr激动剂的自身免疫紊乱的治疗
EP3277272B1 (en) 2015-03-31 2021-08-04 Syros Pharmaceuticals, Inc. Methods of stratifying patients for treatment with retinoic acid receptor-agonists
KR102149321B1 (ko) 2015-10-31 2020-08-28 아이오 테라퓨틱스, 인크. Rxr 아고니스트와 갑상선 호르몬의 조합을 사용한 신경계 질환의 치료
WO2017091762A1 (en) 2015-11-25 2017-06-01 Io Therapeutics, Inc. Use of cyp26-resistant rar alpha selective agonists in the treatment of cancer
KR102549273B1 (ko) 2016-03-10 2023-06-28 아이오 테라퓨틱스, 인크. Rxr 작용제 및 갑상선 호르몬의 조합을 사용한 자가면역 질환의 치료
NZ745704A (en) 2016-03-10 2019-04-26 Io Therapeutics Inc Treatment of muscular disorders with combinations of rxr agonists and thyroid hormones
KR20240157122A (ko) 2016-04-08 2024-10-31 사이로스 파마수티컬스, 인크. Aml 및 mds 치료용 rara 효능제
CA3069672A1 (en) 2017-07-13 2019-01-17 Io Therapeutics, Inc. Receptor subtype and function selective retinoid and rexinoid compounds in combination with immune modulators for cancer immunotherapy
CA3073953A1 (en) 2017-08-31 2019-03-07 Io Therapeutics, Inc. Rar selective agonists in combination with immune modulators for cancer immunotherapy
EP3684348A4 (en) 2017-09-20 2021-08-18 IO Therapeutics, Inc. TREATMENT OF DISEASES WITH ETERS FROM SELECTIVE RXR AGONISTS
US10966950B2 (en) 2019-06-11 2021-04-06 Io Therapeutics, Inc. Use of an RXR agonist in treating HER2+ cancers
EP4444287A4 (en) 2021-12-07 2025-05-28 Io Therapeutics, Inc. USE OF AN RXR AGONIST AND TAXANES FOR THE TREATMENT OF HER2+ CANCER
KR20240115316A (ko) 2021-12-07 2024-07-25 아이오 테라퓨틱스, 인크. 약물 내성 her2+ 암 치료에서의 rxr 작용제의 용도
CN114703227B (zh) * 2022-01-27 2023-11-10 中国科学院生态环境研究中心 基于MCF-7细胞系构建的RARα效应物体外筛选方法
CN119451672A (zh) 2022-06-27 2025-02-14 Io治疗公司 四氢萘酚的合成及其用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000502707A (ja) * 1995-12-29 2000-03-07 ビジョン・ファーマシューティカルズ・リミテッド・パートナーシップ ＲＡＲα受容体特異的または選択的活性を有する化合物による処置方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE617614T1 (de) * 1991-12-18 1995-06-08 Baylor College Of Medicine, Houston, Tex. Mitteln zur modulierung von verfahren durch retinoid rezeptoren und dafür nützliche verbindungen.
US5675024A (en) * 1995-11-22 1997-10-07 Allergan Aryl or heteroaryl amides of tetrahydronaphthalene, chroman, thiochroman and 1,2,3,4,-tetrahydroquinoline carboxylic acids, having an electron withdrawing substituent in the aromatic or heteroaromatic moiety, having retinoid-like biological activity

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000502707A (ja) * 1995-12-29 2000-03-07 ビジョン・ファーマシューティカルズ・リミテッド・パートナーシップ ＲＡＲα受容体特異的または選択的活性を有する化合物による処置方法

Also Published As

Publication number Publication date
CA2405136A1 (en) 2001-10-11
WO2001074759A1 (en) 2001-10-11
US20010039293A1 (en) 2001-11-08
AU2001253045A1 (en) 2001-10-15
EP1268405A1 (en) 2003-01-02
ATE331703T1 (de) 2006-07-15
TWI281911B (en) 2007-06-01
ES2267754T3 (es) 2007-03-16
US6387950B2 (en) 2002-05-14
EP1268405B1 (en) 2006-06-28
CA2405136C (en) 2009-06-16
DE60121145D1 (de) 2006-08-10
EP1650188A1 (en) 2006-04-26
DE60121145T2 (de) 2007-05-31

Similar Documents

Publication Publication Date Title
EP1268405B1 (en) Treatment of tumors with rar alpha selective retinoid compounds in combination with other anti-tumor agents
Simoni et al. Heterocycle-containing retinoids. Discovery of a novel isoxazole arotinoid possessing potent apoptotic activity in multidrug and drug-induced apoptosis-resistant cells
US8389538B2 (en) Rexinoid compound having alkoxy group
RU2163906C2 (ru) Арил- или гетероариламиды тетрагидронафталин-, хроман-, тиохроман- и 1,2,3,4-тетрагидрохинолинкарбоновых кислот, проявляющие ретиноидоподобную биологическую активность
DE69829183T2 (de) Synthese und verwendung von retinoiden mit negativen hormonellen und/oder antagonistischen wirkungen
JP2007527362A (ja) 強力な分化および抗増殖活性をもつ新規ベンズアミド誘導体のヒストン脱アセチル化酵素阻害剤
CN104284893B (zh) 用于治疗皮肤疾病、病症以及病状的肝x受体(lxr)调节剂
CA2443721A1 (en) Sulfonamide derivatives
JPS61197554A (ja) 新規アニリド
Upegui et al. Chroman-4-one hydrazones derivatives: synthesis, characterization, and in vitro and in vivo antileishmanial effects
JP6821737B2 (ja) 肝臓ｘ受容体（ｌｘｒ）のモジュレーター
WO2024040045A2 (en) 2-diarylmethyl-4-aminotetrahydropyran sulfonimidamides as anticancer, antiinflammatory, antifibrotic and neuroprotective agents
Mori et al. Development of retinoic acid receptor antagonists bearing trans-SF4-alkynyl structure as a linear linker
US5703130A (en) Chalcone retinoids and methods of use of same
CN108602775A (zh) 肥大细胞调节剂及其用途
CN101898985A (zh) Bcl-2蛋白的N-取代苯磺酰基-取代苯甲酰胺类小分子抑制剂及其应用
AU2001275081B2 (en) Substituted stilbenes as glucose uptake enhancers
HK1091196A (en) Treatment of tumors with rar alpha selective retinoid compounds in combination with other anti-tumor agents
CN100455564C (zh) 组蛋白去乙酰化酶抑制剂及其药用制剂的制备和应用
AU702423B2 (en) Chalcone retinoids and methods of use of same
Jiang et al. 1-(Phenyl) isoquinoline carboxamides: a novel class of subtype selective inhibitors of thyrotropin-releasing hormone (TRH) receptors
US20040122080A1 (en) Synergist combinations of retinoid receptor ligands and selected cytotoxic agents for treatment of cancer
JP2004506011A (ja) フェニルまたはヘテロ芳香族基と置換クロマニル、チオクロマニルまたはテトラヒドロキノリニル基とでジ置換されたアセチレン化合物を他の抗腫瘍剤と組み合わせて使用する腫瘍の処置
CN108191733B (zh) 一种苯-吡咯戊烷类化合物、其制备方法及抗肝纤维化用途
CN1498105A (zh) 含有类维生素a受体配体和选择的细胞毒性剂的用于治疗癌症的协同联合体系

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080331

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080331

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20101215

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20101221

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110318

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110328

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20110419

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20110426

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110621

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20111018